AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

 AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

Shots:

  • The P-II (NCT02130882) study involves assessing of Fasenra (benralizumab,30mg, q4w) vs PBO in 20 patients with HES who had at least 1,000 eosinophils/µL of blood
  • The P-II (NCT02130882) clinical study results: @12wks. reduction in absolute blood eosinophil counts >50% (90% vs 30%); @48wks.maintained reduction in eosinophil counts (74%); patients taper off other HES therapies (64%), Published at New England Journal of Medicine
  • Fasenra (benralizumab, SC, q4w) is a mAb targeted IL-5 receptor presented at the surface of eosinophils and has also received approval for eosinophilic asthma in US, EU, Japan with FDA’s ODD for HES. Kyowa Hakko in-licensed Fasenra from AZ

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post